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Abstract
Background: In the financing of a national health system, where pharmaceutical spending is one of the main cost
containment targets, predicting pharmacy costs for individuals and populations is essential for budget planning
and care management. Although most efforts have focused on risk adjustment applying diagnostic data, the
reliability of this information source has been questioned in the primary care setting. We sought to assess the
usefulness of incorporating pharmacy data into claims-based predictive models (PMs). Developed primarily for the
U.S. health care setting, a secondary objective was to evaluate the benefit of a local calibration in order to adapt
the PMs to the Spanish health care system.
Methods: The population was drawn from patients within the primary care setting of Aragon, Spain (n = 84,152).
Diagnostic, medication and prior cost data were used to develop PMs based on the Johns Hopkins ACG
methodology. Model performance was assessed through r-squared statistics and predictive ratios. The capacity to
identify future high-cost patients was examined through c-statistic, sensitivity and specificity parameters.
Results: The PMs based on pharmacy data had a higher capacity to predict future pharmacy expenses and to
identify potential high-cost patients than the models based on diagnostic data alone and a capacity almost as
high as that of the combined diagnosis-pharmacy-based PM. PMs provided considerably better predictions when
calibrated to Spanish data.
Conclusion: Understandably, pharmacy spending is more predictable using pharmacy-based risk markers
compared with diagnosis-based risk markers. Pharmacy-based PMs can assist plan administrators and medical
directors in planning the health budget and identifying high-cost-risk patients amenable to care management
programs.
Background
Pharmaceutical public spending is recognised as one of
the main cost containment targets in the financing of
national health systems such as that in Spain. However,
studies aimed at understanding population patterns of
drug consumption, costs and morbidity are uncommon.
Recent pharmaceutical reimbursement reforms in Spain
have focused on measures oriented towards the industry
side, giving less importance to the role of patient need
and demand [1]. Patient characteristics are not taken
into consideration for pharmacy budget allocation to
health centres either, ascribing fundamental weight to
prior year costs [2].
By taking into account the risk factors for a covered
population, prospective risk adjustment methodologies–
commonly referred to as “predictive models” (PMs)–can
be helpful for health budget planning and case profiling
[3]. These tools can also be used as population-based
screens meant to identify enrolees who pose a relatively
higher risk of generating large future pharmacy expendi-
tures [4,5]. Such patients would benefit from case man-
agement programs that could enhance primary care in
order to improve the quality and coordination of ser-
vices [6-8]. As far as physicians are concerned, PMs pro-
vide a means of considering health status when
assessing drug expenditure, providing health care
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pharmaceutical benefits.
In this manuscript, we use Adjusted Clinical Group
PMs developed at Johns Hopkins University because of
their acknowledged validitya n de x t e n s i v eu s ea sar i s k
adjustment technology [9,10]. To date, health services
research in the Spanish context has focused on using
diagnoses-based risk assessment variables [3,11]. How-
ever, risk assessment models such as the ACG-PMs,
which integrate routinely collected pharmacy data, may
be more appropriate. Chronic conditions are associated
with specific pharmacotherapy protocols and, further-
more, diagnostic data often lack complete documenta-
tion [12]. This is due not only to the fact that chronic
diseases are frequently not explicitly named in physi-
cians’ medical records [13], but also because individual
data are frequently fragmented across different health
care information systems–primary care, secondary care,
emergencies etc.–. In contrast, studies carried out in
C a n a d a[ 1 4 , 1 5 ]s h o w e dt h a tp rescription claims repre-
sent one of the most accurate means of determining
what drugs are dispensed to individuals, because phar-
macists almost always dispense the medication that is
prescribed and this information is reliably transmitted to
the drug claims database.
Last, the application of these tools in a different health
system from the one where they were originally devel-
oped requires the use of local weights for the analysed
risk factors. Thus, the role of a calibration may also be
appraised in order to maximise the predictive accuracy
of the PMs.
The objective of this paper was first to assess the use-
fulness of incorporating pharmacy data into our efforts
to better understand health care resource utilisation and
patients’ use of pharmacy resources in particular and,
second, to evaluate the benefit of a local calibration of
PMs in order to adapt them to the Spanish health care
system.
Methods
Data Source and Study Sample
Data were obtained from the Electronic Medical
Records of patients from six primary care health centres
belonging to Aragon’s Public Health Care System for
the years 2006 (Year-1) and 2007 (Year-2). In order to
increase the reliability of the data, health centres were
selected according to their experience with the use of
Electronic Medical Records, which, in all cases, was
longer than three years. The sample was restricted to
enrolees seen at least once by a public general practi-
tioner (family doctor or paediatrician) during both Year
1 and Year 2, which resulted in a final sample of 84,152.
Among the 84,152 patients 9.4% had no pharmacy
expenditure in 2006 and 9.3% had no pharmacy
expenditure in 2007. Data were obtained from adminis-
trative registries of the Aragon Health Care System after
official request and authorization. Personal information
was anonymised according to the Spanish Organic Law
of Personal data Protection 15/1999. This work is part
of a project funded by the Carlos III Health Institute
which has been approved by the Ethics Committee of
Aragon (CEICA).
The Year-1 inputs for the PMs were patients’ gender,
their age, all assigned diagnoses and the codes for the
drugs they consumed according to the ATC Classifica-
tion System [16]. Diagnoses were originally coded
according to the International Classification of Primary
Care (ICPC-2) [17]; the codes were subsequently trans-
formed to correspond with the International Classifica-
tion of Disease (ICD-9-CM) [18]. We used patients’
annual pharmacy expenditures from Year-1 to calculate
prior pharmacy cost predictors. Year-2 expenditures
were only used as a validation tool, in order to assess
the performance of the PMs.
To obtain information on pharmacy charges, data
from Electronic Medical Records were crossed with the
information in the National Pharmacy Database. Regis-
tries were made anonymous with the aim of ensuring
the confidentiality of the information. These costs corre-
spond to the retail price of drugs consumed and phar-
macy accessories used by patients. Even if drug claims
collect prescriptions carried out by both specialised and
general practitioners, the majority of these prescriptions
are filled by the latter (92.6% in 2006 and 92.7% in
2007, according to the Pharmacy Database of Aragon).
Risk Factors Within the Predictive Models
Based on the abovementioned input variables, the ACG
case-mix system, version 8.1®, assigns risk measurement
variables related to specific demographic, diagnoses, and
pharmacy use patterns.
Diagnosis-based risk factors include Adjusted Clinical
Groups implying the highest levels of medical need
( A C G sa r eas e r i e so fm u t u a l l y exclusive health status
categories defined by morbidity, age, and sex [9,10]),
specific Expanded Diagnostic Clusters representing
uncommon diseases that signify high disease severity
(EDCs are groupings of ICD-9-CM codes according to
clinical similarity [19]), and the hosdom and patient
frailty markers (the hosdom marker is a count of differ-
ent morbidity types associated with a >50% probability
of future hospital admission among patients and the
frailty marker clusters diagnostic codes that indicate the
presence of at least 1 to 11 frail conditions [19]).
As for medication-derived risk factors, several phar-
macy-based morbidity groups (Rx-MG) are included.
Rx-MGs are created to account for the anatomical-phy-
siological system drugs act on, as well as the morbidity
differentiation, the expected duration and the severity of
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four clinical dimensions not only characterise medica-
tions by morbidity type but also have major conse-
quences for predictive modelling. Higher levels of
differentiation and chronicity, as well as greater severity,
would all be expected to increase resource use [19].
Whereas DxRx-PMs include the whole set of risk fac-
tors, Dx-PMs and Rx-PMs will only use diagnostic or
pharmacy-based variables, respectively.
Data Analysis
To understand the differences between the U.S. and
Spanish health care systems, we first described, for each
of the settings, each patient’s demographic and clinical
characteristics from Year-1 as well as the distribution of
the pharmacy expenditures from Year-2. U.S. data,
which were originally used for the empirical develop-
ment of the ACG-based PMs, were obtained from the
PharMetrics Patient-Centric Database. This database
represents the medical and pharmacy claims and enrol-
ment records across the continuum of medical care for
approximately 85 geographically diverse health plans
within the U.S.
Pharmacy data were used as a means of assessing the
validity of diagnoses recorded in physicians’ medical
records. Comparisons were made between patients iden-
tified as having specific chronic conditions using diagno-
sis codes (ICD-9-MC), pharmacy codes (ATC
Classification System), and both diagnoses and phar-
macy codes.
Next, we looked at how useful Rx-PMs were for pre-
dicting future pharmacy expenditures. Multivariate lin-
ear regression was employed to obtain r-squared
statistics by regressing Year-2 pharmacy charges on the
PMs’ risk factors.
We also calculated predictive ratios (PRs) to assess
model accuracy. We used Year-2 as the validation sam-
ple and applied models estimated from Year-1 to gener-
ate predictions for each patient and PRs for 3 types of
cohorts defined by a) the presence of a relevant diagno-
sis, b) the presence of a relevant drug claim and c) phar-
macy costs in Year-1 arrayed by percentiles.
Classification accuracy was examined using logistic
regression in which the dependent variable was defined
by assignment (or not) to the top 5% risk group in
terms of Year-2 charges (high consumer yes/no). Model
fit was examined through c-statistic, sensitivity and spe-
cificity parameters.
For each of the mentioned measures, results from a
local calibration of the model were compared with
results based on the U.S. health care system.
Finally, we performed a sensitivity analysis to measure
how results would vary when using U.S. weights derived
from a Medicare managed care population for indivi-
duals over the age of 65. This is an alternative to the
commercial reference weights obtained from the Phar-
Metrics Patient-Centric Database, which is available as
part of the ACG software for predominantly elderly
populations.
Results
The ACG case-mix system proved to have high perfor-
mance in recognising and assigning 100% of the diag-
noses and 92.5% of the pharmacy codes.
The Spanish and U.S. datasets had similar distribution
in terms of age, sex and chronic conditions (Table 1).
With regard to the prevalence of cited diseases, numbers
were comparable except for depression: compared with
what was found in the U.S. data, the proportion of the
study sample having this condition was nearly two times
higher for the young Spanish population and around
four times higher for the elderly Spanish population. In
both Spanish and U.S. datasets, the distribution of the
pharmacy expenditure showed a pronounced skewness,
especially among the under-65 population, where nearly
half of annual expenditures on prescription drugs were
generated by only 5% of the study population. Regarding
the elderly population, U.S. data showed a more skewed
d i s t r i b u t i o n ,w i t hh a l fo ft he study population being
responsible for almost 90% of pharmacy expenses.
These numbers are consistent with the well-known dis-
tribution properties of pharmacy costs in a population.
With regard to comparisons between “who” was iden-
tified as having a particular medical condition using
diagnostic data from electronic medical records and
“who” was identified as having a medical condition
using pharmacy claims, we found that, for several
chronic conditions such as depression or asthma, some
patients taking drugs have no diagnoses associated with
these drugs. On the other hand, a high percentage of
individuals to whom the diagnosis of hyperlipidaemia
has been assigned are not taking lipid-lowering drugs
according to pharmacy claims (Figure 1).
Across all PMs, the DxRx model explained the most
variance (Table 2). However, the capacity of the RxPM
to predict future pharmacy expenditures was almost as
high as that of the DxRx combined model (40.6% vs.
42.6%). In all cases, models provided considerably better
predictions when applying weights resulting from local
calibrations.
Table 3 shows means and PRs for Year-2 pharmacy
expenditures based on information from the prior year.
T h em o s te x p e n s i v eo ft h e s eg r o u p s( t h o s ew h oh a d
congestive heart failure, were taking drugs for congestive
heart failure or were in the top 1% of spending during
Year-1) incurred costs between 4 and 15 times higher
than the average of 390€. The diagnosis-based model
(Dx-PM) predicted pharmacy expenditures more accu-
rately for the diagnosis-identified groups, but somewhat
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Spanish Data U.S. Data
Under 65 population Over 65 population Under 65 population Over 65 population
Demographic Characteristics (Year-1)
Age (years) %
0-4 6.8 — 6.6 —
5-11 7.6 — 11.6 —
12-17 6.2 — 10.3 —
18-34 28.8 — 24.5 —
35-44 16.2 — 19.5 —
45-54 16.8 — 17.3 —
55-64 17.6 — 10.2 —
65-69 — 24.3 — 24.0
70-74 — 27.3 — 28.9
75-79 — 22.6 — 22.3
80-84 — 15.7 — 14.6
>85 — 10.1 — 10.2
Age (years) mean 34.5 75.0 31.5 75.4
Female % 54.9 58.5 51.5 57.8
Clinical characteristics (Year-1)
Chronic conditions %
None 59.3 8.3 68.1 13.3
1 24.4 19.1 17.4 14.1
2 or more 16.3 72.6 14.5 72.6
Mean no. of chronic conditions 0.7 2.7 0.6 3.2
Prevalence of the diseases:
Hypertension % 9.2 54.8 7.7 53.9
Hyperlipidaemia % 10.6 32.7 7.3 35.0
Depression % 6.3 11.9 3.6 3.3
Diabetes % 3.3 18.4 2.7 18.4
Asthma % 5.0 4.2 3.7 4.0
CHF % 0.2 3.8 0.3 7.2
Pharmacy expenditure (Year-2)
Mean pharmacy expenditure 228 € 950 € 365 € ($467) 840 € ($1,077)
Mean pharmacy expenditure of: % of total € % of total € % of total $ % of total $
Highest 1% 4,998 € 21.9 6,838 € 7.2 7,608 €
($10,077)
21.5 11,137 €
($14,764)
13.7
Highest 5% 2,255 € 49.5 4,064 € 21.4 3,399 €
($4,502)
48.1 4,677 €
($6,200)
28.8
Highest 10% 1,518 € 66.7 3,214 € 33.8 2,312 €
($3,062)
65.4 3,302 €
($4,377)
40.6
Highest 30% 693 € 91.3 2,083 € 65.8 1,090 €
($1,443)
92.4 1,922 €
($2,548)
71.0
Highest 50% 443 € 97.2 1,601 € 84.3 701 €
($928)
99.0 1,444 €
($1,914)
88.9
Source of currency rate: XE.com Currency Services as of 23/01/2009.
CHF: Congestive Heart Failure.
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Analogously, the drug-based model (Rx-PM) was more
accurate with the groups defined by their use of drugs
in comparison with the groups defined by medical con-
ditions. The benefit of a local calibration was persistent
in all cases.
Table 2 also shows the area under ROC curve and
sensitivity and specificity values of each of the models
evaluated for the top 5% Year-2 cost group. Whereas
the 3 models exhibited similar performance on the spe-
cificity test, performance on sensitivity diverged: the
DxRx-PM and the Rx-PM using Spanish weights showed
the best performance (53.2% and 52.3% respectively).
This is confirmed by the corresponding ROC curve
values (0.949 and 0.941 respectively). Once again, there
was little improvement in sensitivity or ROC curve
values for the Rx-PM when adding the diagnostic infor-
mation with regard to the prediction of pharmacy
expenditure. The results were notably enhanced when
Spanish weights were applied.
Discussion
No previously published research assesses the usefulness
of incorporating pharmacy data into prospective risk
adjustment techniques in any national health system. To
date, research in the European and Spanish contexts has
focused on using diagnoses-based risk assessment vari-
ables [3,11]. However, our study, as well as others car-
ried out within the Spanish National Health System
[20], determined that the accuracy of the diagnostic
codes allocated by primary health care physicians in
their computerised medical records could be improved.
The results of this study confirm that much can be
learned by looking at pharmacy data, especially when
forecasting drug expenditures. Studies carried out in the
U.S [21,22] and Europe [23] have outlined the potential
of pharmacy data to improve the system of risk adjust-
ment for both care management program capitation
payments and pharmacy budget planning. This is of par-
ticular interest in a situation in which the information
related to drug consumption is routinely recorded and
automated, as it is in Spain. Moreover, the fact that the
applied drug classification system (ATC classification) is
uniform and used all over the country makes the use of
pharmacy data very feasible–even more so if we con-
s i d e rt h er e g u l a ru p d a t i n go ft h en a t i o n a lA T Cc o d e
databases issued by the Ministry of Health, according to
the Guidelines of the World Health Organisation [24].
Nevertheless, several challenges are posed by medica-
tion-only PMs. First, using pharmacy data as a risk
adjuster for resource allocation could create perverse
incentives, encouraging inappropriately prescribed drugs
Figure 1 Prevalence of chronic disease in the general population according to diagnosis and pharmacy data.
Table 2 Statistical performance of Alternative Predictive Models using U.S./Spanish weights.
Alternative Predictive Models
Dx-PM Rx-PM DxRx-PM
U.S. Weights Spanish Weights U.S. Weights Spanish Weights U.S. Weights Spanish Weights
Variance explained. R
2 18.9% 29.4% 22.2% 40.6% 23.5% 42.6%
Area Under ROC Curve* .868 .902 .900 .941 .903 .949
Sensitivity* 30.6% 39.4% 27.5% 52.3% 31.2% 53.2%
Specificity* 96.3% 96.8% 96.2% 97.5% 96.4% 97.5%
Mean pharmacy expenditure Year-2 (€)*
True positives 3,059 3,076 3,244 3,236 3,248 3,244
True negatives 233 233 236 234 235 234
*Outcomes refer to top 5% Year-2 pharmacy cost group. The Area Under ROC Curve ranges from 0.5 (model no better than the flip of a coin) to 1.0 (perfect true
positive and true negative classification).
Dx: physician assigned diagnosis. Rx: pharmacy prescriptions filled by physicians. PM: predictive model.
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p r o p r i a t eu s eo ft h e s ed r u g si nt h ef u t u r e .I nc o n s e -
quence, if pharmacy data are to be used for budget
allocation purposes, intensive monitoring activity will be
required to prevent the inappropriate prescribing of
drugs. As it happens in other European countries [23],
in Spain, social security funds are not care providers
themselves unlike Health Maintenance Organizations
(HMO) in the U.S.; this may reduce the danger of inap-
propriate prescription behaviour.
Second, pharmacy claims data may not always portray
an accurate clinical picture, because some prescribed
medications have multiple indications from which a
patient’s disease status must be inferred and because
one disease may have many medication options in terms
of its management [25]. One of the most important
innovations presented by the Rx-PM from the ACG sys-
tem is its clinically oriented approach, which captures
the unique clinical information embedded in medica-
tion-use data instead of attempting to identify diseases/
conditions based on medications [19].
The benefits of local calibrations have become evident.
As was the case with other risk adjustment tools, such
as the Diagnosis-Related Groups used in acute care
hospitals, adaptation processes have been developed by
other countries on the grounds that the philosophy of
health care, resource consumption patterns and funding
approaches differ from those in the country where the
tool was originally created [26]. Indeed, importing clini-
cal predictors related to weights resulting from empirical
evaluations carried out with U.S. cost data could lead to
the incorporation of U.S. funding incentives and disin-
centives into the Spanish health care system. The results
of our work show that the statistical performance of
PMs was optimised using Spanish weights. This is due
to the fact that local weights were calculated by regres-
sing pharmacy cost data from our own health system on
the explanatory variables for ACG-PMs.
Moreover, our sensitivity analysis demonstrated that
these results were fairly robust even when using U.S.
weights derived from a Medicare managed care popula-
tion for individuals over the age of 65.
Limitations
The main limitation of this study is related to the infea-
sibility of applying a split half method, which involves
dividing the total sample in two and correlating the
results, as a way of assessing the reliability of a test. In
order to apply this technique to our particular study,
Table 3 Predictive Ratios for Year-2 pharmacy costs for Disease, Drug Use and Cost Defined Groups.
Alternative Predictive Models
Dx-PM Rx-PM DxRx-PM
n Mean pharmacy expenditure Year-2 (€) U.S.
Weights
Spanish
Weights
U.S.
Weights
Spanish
Weights
U.S.
Weights
Spanish
Weights
Medical condition groups
Hypertension 16,519 931 0.773 0.999 0.856 0.989 0.864 1.000
Hyperlipidaemia 13,175 811 0.776 0.925 0.900 1.007 0.911 1.010
Depression 6,326 876 0.847 1.000 0.961 0.979 1.009 1.000
Diabetes 5,724 1,180 0.714 1.000 0.774 0.984 0.793 1.000
Asthma 4,090 522 0.951 1.000 0.921 0.959 0.986 1.000
CHF 864 1,396 1.031 1.000 0.755 0.958 0.774 1.000
Drug utilisation groups
Antihypertensives 18,209 990 0.721 0.918 0.856 1.000 0.859 1.000
Lipid-lowering 9,912 1,084 0.638 0.811 0.843 1.000 0.853 1.000
Antidepressants 8,717 1,023 0.646 0.774 0.920 1.000 0.936 1.000
Antidiabetics 4,947 1,267 0.654 0.917 0.785 0.998 0.797 1.002
Antiasthmatics 7,303 755 0.716 0.820 0.870 1.000 0.874 1.000
CHF 3,981 1,349 0.687 0.822 0.773 1.000 0.774 1.000
Year-1 spending percentiles
Highest 1% 841 5,708 0.175 0.240 0.247 0.345 0.249 0.368
Highest 5% 4,207 3,026 0.301 0.421 0.419 0.548 0.421 0.572
Highest 10% 8,415 2,221 0.378 0.519 0.517 0.642 0.519 0.665
Highest 30% 25,245 1,168 0.582 0.736 0.735 0.835 0.738 0.846
Highest 50% 42,075 766 0.746 0.859 0.882 0.935 0.886 0.938
Predictive ratios reflect the ratio of expected pharmacy cost divided by the actual cost for each cohort (PR = 1 indicates perfect prediction, PR<1 indicates
underprediction and PR>1 indicates overprediction). Medical condition groups consist of patients with at least 1 relevant diagnosis in Year-1; drug utilisation
groups include those with at least one relevant pharmacy fill in Year-1.
Dx: physician assigned diagnosis. Rx: pharmacy prescriptions filled by physicians. PM: predictive model. CHF: Congestive Heart Failure.
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patients so that each of the split groups would surpass
the minimum number of individuals required for predic-
tive modelling. On the other hand, the study population
is not representative of either the population of the Ara-
gon region or that of Spain, so results must be cau-
tiously interpreted. Moreover, given the applied patient
inclusion criteria (i.e. enrolees seen at least once by a
public general practitioner during both Year 1 and Year
2), 7.9% of the enrolees that went to the health centre
in 2006 (Year-1) and 14.3% of the enrolees that went in
2007 (Year-2) were excluded from the study sample due
to their non-attendance in 2007 and 2006 respectively.
Future studies may consider including patients with a
discontinuous utilization of health care services when
measuring the performance of PMs.
Nevertheless, the validity of the sample is backed up
by the fact that the proportion of women, the age distri-
bution, the prevalence of chronic conditions and the
behaviour of patients with regard to pharmacy expendi-
ture are consistent with those of previous studies carried
out in the Spanish primary care setting [3,11].
Another potential limiting factor could be related to
the relatively recent incorporation of electronic medical
records into the primary care setting. Even if a series of
inclusion criteria were applied during the health centre
selection process to guarantee the quality and reliability
of the clinical data, a three-year period of experience in
the use of electronic records is still short enough that
we might question the maturity of the information sys-
tems. This could lead to an overestimation of the clini-
cal under-coding effect highlighted in this study. Thus,
u s i n ge v e ns l i g h t l ym o r er e c e n td a t ac o u l ds u b s t a n t i a l l y
boost model performance measures.
An additional reason for overestimating the under-
coding phenomenon arises from the lack of connection
between databases for primary and specialised care.
Although the primary care general practitioners are con-
sidered the gatekeepers of the health system and would
therefore need to have a recompilation of all diagnostic
episodes of a patient, certain codes could be missing
when these disease are followed by specialised physi-
cians. In the study region, specialised physicians have
poorer information systems than primary care physi-
cians and, consequently, data are less available. Still,
drug claims collect prescriptions carried out by both
specialised and general practitioners. This situation
could explain cases in which patients consume drugs for
diseases that are not registered in general practitioners’
office records, as reported in this paper.
Even if these two previous statements have been con-
sidered as potential limitations of the study due to their
association with a poor quality of the data, they support
the need to incorporate pharmacy data when carrying
out risk adjustment.
Implications for the Spanish National Health System
When the target of a health care organisation is the
management of an individual’s medication use, predic-
tive models based on pharmacy data are particularly
useful. Adding diagnostic markers to medication data
does not appear to improve predictions for pharmacy
costs [21,22], which tend to show a pronounced degree
of persistence from year to year, particularly among the
heaviest users [27]. This has long been the rationale for
using prior costs in themselves for budget planning by
hospitals and the primary care setting in Spain [2]. In
terms of statistical performance, prior cost is a fairly
good predictor of future cost–even better than diagnos-
tic or pharmacy-related variables [3]–,b u ti th a ss o m e
l i m i t a t i o n s .F i r s t ,p r i o rc o s th a sn oi n h e r e n tc l i n i c a l
meaning, and is therefore of low relevance to clinicians
w h ow i s ht oi n t e r v e n e .I ti sn o tt i e dt om o r b i d i t ya n d ,
thereby, cannot be translated into clinical action. Sec-
ond, prior cost is subject to the phenomenon of regres-
sion to the mean (i.e., the natural tendency of groups of
individuals who are high cost one year to move towards
mean costs in the following years). Third, prior-use
measures are not entirely appropriate as risk factors for
risk-adjusted rate setting or profiling as they potentially
could provide incentives to excessive and inappropriate
pharmacy use.
Screening tools based on diagnostic or medication
data can identify reliable “early warning signs” of future
expenses that can then promote secondary prevention
through patient care management [4]. Although the
beneficial effects of care management have not been
consistently demonstrated[28], preliminary evidence
from an intensive nurse-based intervention for high-risk
elderly individuals appears to show that it holds great
promise in terms of cost reduction[29] and better qual-
ity of care [30]. A randomised clinical trial carried out
recently in the Spanish primary care setting has con-
firmed the effectiveness of intervention strategies in
decreasing the number of consultations of frequent
attenders[31], paving the way for the implementation of
further cost efficiency-focused strategies.
Moreover, the optimal predictive capacity of the ACG-
PM proves its usefulness for future budget planning.
This has been demonstrated to entail the largest impact
on pharmaceutical revenues among existing pharmacy
regulatory measures[32].
Last, PMs provide a means of determining physician
prescription profiles while adjusting for patient case-
mix, so decisions about incentives, efficiency improve-
ment efforts or even sanctions can be targeted towards
the “right” physicians [33].
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Pharmacy-based PMs can assist plan administrators and
medical directors in planning the health budget and
identifying high-cost-risk patients amenable to care
management programs.
An application focussing on the total expenditure of
the primary care setting is the next research approach
required. While pharmacy spending is particularly pre-
dictable from drug data, diagnoses may be more useful
than drugs for predicting other medical costs and total
costs [4,22,34]. There could also be factors, such as
behavioural risks or functional health status, that risk
models do not yet capture well, and whose influence on
pharmacy consumption ought to be considered in future
studies.
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